Metabolic Syndrome Risk Factor in IGT: STOP-NIDDM Trial
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The aim of the study was to analyse the independent and joint effects of the components of
the metabolic syndrome (MetS) on the incidence of diabetes in people with impaired glucose
tolerance (IGT) and to assess the effect of acarbose by MetS status.
Double-blind placebo controlled trial, 1,368 patients, follow-up time 3.3 years. MetS by ATP
III definition with fasting plasma glucose of ≥ 6.1 mmol/l as limit for impaired fasting
glucose (IFG).